Quratis Inc. Logo

Quratis Inc.

Biopharmaceutical firm developing vaccines and therapeutics for infectious diseases.

348080 | KO

Overview

Corporate Details

ISIN(s):
KR7348080003
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 의료단지길 143 -, 청주시

Description

Quratis Inc. is a biopharmaceutical company specializing in the research and development of vaccines and therapeutic agents for infectious diseases. The company's lead pipeline candidate is QTP101, a novel tuberculosis (TB) vaccine developed for adolescents and adults, an area with significant unmet medical needs. Quratis operates its own GMP-certified manufacturing facility, enabling the production of various biologics such as DNA plasmids, RNA, and proteins to support its development programs. The company is advancing the global commercialization of its TB vaccine through strategic partnerships and technology transfers, with notable progress in key Asian markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-07-24 00:00
주식등의대량보유상황보고서(약식)
Korean 53.6 KB
2023-07-21 00:00
주식등의대량보유상황보고서(일반)
Korean 207.4 KB
2023-07-19 00:00
주식등의대량보유상황보고서(약식)
Korean 59.5 KB
2023-07-19 00:00
주식등의대량보유상황보고서(약식)
Korean 61.8 KB
2023-07-14 00:00
[기재정정]사업보고서 (2022.12)
Korean 1.1 MB
2023-07-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2023-07-07 00:00
투자판단관련주요경영사항(임상시험계획변경승인)(청소년 및 성인을 대상으로 하는 QTP101(결핵예방백신) 제 2b/3상 임상시험계획서(IND) …
Korean 15.3 KB
2023-06-26 00:00
투자판단관련주요경영사항(임상시험계획승인신청)(장년 및 노년을 위한 QTP101 결핵백신의 제 2a상시험)
Korean 8.8 KB
2023-06-23 00:00
[기재정정]주식등의대량보유상황보고서(약식)
Korean 60.3 KB
2023-06-22 00:00
주식등의대량보유상황보고서(약식)
Korean 61.9 KB
2023-06-22 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 285.6 KB
2023-06-22 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.4 KB
2023-06-22 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.3 KB
2023-06-22 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.3 KB
2023-06-22 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.3 KB

Automate Your Workflow. Get a real-time feed of all Quratis Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quratis Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quratis Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.